The future is now: Model-based clinical trial design for Alzheimer's disease

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 3, 2015, Pages 210-214

  Romero, K ^a   Ito, K ^b   Rogers, J A ^c   Polhamus, D ^c   Qiu, R ^b   Stephenson, D ^a   Mohs, R ^d   Lalonde, R ^b   Sinha, V ^e   Wang, Y ^e   Brown, D ^f   Isaac, M ^f   Vamvakas, S ^f   Hemmings, R ^f   Pani, L ^f   Bain, L J ^a   Corrigan, B ^b  

^a CRITICAL PATH INSTITUTE   (United States)

^b PFIZER INC   (United States)

^c Metrum Research Group   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; HUMAN; PRIORITY JOURNAL; SIMULATION; STUDY DESIGN; COMPUTER SIMULATION; DRUG APPROVAL; EUROPE; FOOD AND DRUG ADMINISTRATION; LEGISLATION AND JURISPRUDENCE; PROCEDURES; UNITED STATES;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DRUG APPROVAL; EUROPE; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84927681963     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.16     Document Type: Article

References (9)

1. Romero, K. et al. The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases. Clin. Pharmacol. Ther. 86, 365–367 (2009).
2. Neville, J. et al. Development of a unified clinical database for Alzheimer's disease. Alzheimer's Dement. 2015 (in press).
3. Rogers, J.A. et al. Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a beta regression meta-analysis. J. Pharmacokinet. Pharmacodyn. 39, 479–498 (2012).
4. Samtani, M.N. et al. An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative. J. Clin. Pharmacol. 52, 629–644 (2012).
5. Holford, N.H. & Peace, K.E. Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc. Natl. Acad. Sci. USA. 89, 11466–11470 (1992).
6. Food and Drug Administration: draft guidance for industry. Alzheimer's disease: developing drugs for the treatment of early stage disease. . Accessed 24 February 2013.
7. Rascol, O. et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 10, 415–423 (2011).
8. Qualification of novel methodologies for medicine development. .
9. Qualification opinion of a novel data-driven model of disease progression and trial evaluation in mild-to-moderate Alzheimer's disease. .